A 20-gene gene expression-based assay accurately and robustly assigns COO subtypes of DLBCL using formalin-fixed paraffin-embedded tissue.
Keypoint:
A 20-gene gene expression-based assay accurately and robustly assigns COO subtypes of DLBCL using formalin-fixed paraffin-embedded tissue.
Abstract:
The assignment of diffuse large B-cell lymphoma into cell-of-origin (COO) groups is becoming increasingly important with the emergence of novel therapies that have selective biological activity in germinal center B-cell-like (GCB) or activated B-cell-like (ABC) groups. The LLMPP's Lymph2Cx assay is a parsimonious digital gene-expression (NanoString) based test for COO assignment in formalin-fixed paraffin-embedded tissue (FFPET) routinely produced in standard diagnostic processes. The 20-gene assay was trained using 51 FFPET biopsies; the locked assay was then validated using an independent cohort of 68 FFPET biopsies. Comparisons were made with COO assignment using the original COO model on matched frozen tissue. In the validation cohort the assay was accurate, with only one case with definitive COO being incorrectly assigned, and robust, with >95% concordance of COO assignment between 2 independent laboratories. These qualities, along with the rapid turn-around-time, make Lymph2Cx attractive for implementation in clinical trials and, ultimately, patient management. , has profound biological 4 , prognostic 5, 6 and potential therapeutic implications [7] [8] [9] . New therapeutic agents with selective activity in ABC and GCB DLBCL are under development. The original methods used to define these entities performed gene expression profiling (GEP) using microarrays on RNA derived from frozen tissue (FT). Subsequently, in an attempt to determine COO in standard practice using commonly available formalin-fixed paraffin-embedded tissue (FFPET) we and others used less precise 10 but relatively inexpensive binary immunohistochemical (IHC) methods [11] [12] [13] . Recently, the feasibility of quantitating gene expression in
FFPET in lymphoma has been demonstrated [14] [15] [16] [17] [18] . We sought to create a robust, highly accurate, validated molecular assay for COO distinction using GEP techniques applicable to FFPET 19 .
Methods:
Studies were performed on FFPET biopsies of de novo DLBCL cases that had been classified using the original GEP methods and published algorithm (the Table S1 . This study was approved by the Institutional Review Boards of the participating centers in accordance with the Declaration of Helsinki.
Results and Discussion:
All FFPET biopsies yielded sufficient RNA at both laboratories for the NanoString technology analyses. A pilot study, using the training cohort, When considering the 58 cases designated as ABC or GCB by the "gold standard" method, the Lymph2Cx assay incorrectly assigned one case -an ABC by FT GEP assigned to GCB ( Figure 1A ). At 2%, this favorably compares with the 9%, 6% and 17% rates of misassignment by the "Hans", "Tally" and "Choi" IHC-based algorithms, respectively ( Figure 1A ) [11] [12] [13] . Of note, the accuracy of the IHC-based algorithms observed here is consistent with the original descriptions [11] [12] [13] but superior to that seen in a recent report that also used FT-based COO designation as the comparator 10 . In replication of the original COO model and distinct from the binary IHC models, the Lymph2Cx assay recognizes a group of unclassified cases, where confident assignment cannot be made to either the ABC or GCB subtype. Among the 58 cases, three (5%) at the MoCha site and four (7%) at the CLC site were designated as unclassified. Full assignment data, including that of the unclassified cases by the "gold standard method", are shown in Table S2 .
For personal use only. on April 9, 2017. by guest www.bloodjournal.org From It has become increasingly apparent that pre-analytical, analytical and interobserver variability contribute to poor reproducibility of COO assignment by IHC methods 21 . The independent testing of the FFPET biopsies at 2 laboratories, beginning after the scrolling of the blocks, allowed determination of interlaboratory concordance and the robustness and portability of the assay. The Lymph2Cx scores produced at the two sites show a very high degree of concordance ( Figure 1B) .
Outcomes in the validation cohort were used to determine whether the COO assignments made by the Lymph2Cx assay maintained the prognostic significance previously demonstrated for the original FT sample based method 6 .
The "gold standard method" and Lymph2Cx defined ABC groups both had significantly worse outcome than the GCB groups (Figure 2) . Larger cohorts will need to be examined to provide the statistical power to determine whether this prognostic power is independent of other biomarkers, particularly the International Prognostic Index
22
. Outcomes in the COO groups assigned by IHC were not significantly different in this cohort ( Figure S1 ).
In summary, herein we have described a robust method for COO assignment, applicable to FFPET biopsies that are generated as part of routine diagnostic workflow. Tested against the "gold standard" FT Affymetrix-based method, the rates of correct assignment are very high and the prognostic significance is maintained. Thus, the Lymph2Cx assay brings to fruition the potential to use gene expression-based COO assignment, first described over a decade ago 
